Jeil Pharm (002620) — Cash Flow Reinvestment Rate
Jeil Pharm (002620) has a Cash Flow Reinvestment Rate of 8.93x as of March 2026, reinvesting ₩3.99 Billion (capex ₩1.72 Billion plus investments ₩-2.27 Billion) from operating cash flow of ₩447.08 Million. See Jeil Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Jeil Pharm Cash Flow Reinvestment Rate (2011–2025)
Historical reinvestment intensity for Jeil Pharm across 8 annual periods. For the full cash flow conversion analysis, see Jeil Pharm cash flow conversion.
Annual Cash Flow Reinvestment Rate for Jeil Pharm (2011–2025)
Year-by-year capital reinvestment analysis for Jeil Pharm. See 002620 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 41.01x | ₩16.00 Billion | ₩390.26 Million | ₩9.33 Billion | ▲ +1111.8% |
| 2024 | 3.38x | ₩15.37 Billion | ₩4.54 Billion | ₩6.86 Billion | ▲ +32.6% |
| 2021 | 2.55x | ₩34.19 Billion | ₩13.40 Billion | ₩23.69 Billion | ▲ +44.8% |
| 2019 | 1.76x | ₩44.43 Billion | ₩25.22 Billion | ₩37.69 Billion | ▲ +107.5% |
| 2017 | 0.85x | ₩5.03 Billion | ₩5.92 Billion | ₩2.94 Billion | ▼ -84.0% |
| 2016 | 5.30x | ₩60.20 Billion | ₩11.36 Billion | ₩30.33 Billion | ▲ +87.4% |
| 2015 | 2.83x | ₩7.76 Billion | ₩2.74 Billion | ₩6.74 Billion | ▲ +159.0% |
| 2011 | 1.09x | ₩25.82 Billion | ₩23.63 Billion | ₩22.40 Billion | — |